rheumatic disease of the joints Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1.Men and women, * 18 years of age 2.Diagnosis of rheumatoid arthritis according to the ACR criteria (Arnett et al 1988) 3.Treatment with disease modifying anti-rheumatic drugs (DMARDS) and in addition, corticosteroids up to 10 mg daily and non-steroidal anti-inflammatory drugs (NSAIDs) is permitted, provided that there is a stable dose for at least 2 weeks. Patients should have been treated previously with at least one anti-tumour necrosis factor (anti-TNF) medication with inadequate response or intolerance. Anti-TNF should be discontinued at least 4 weeks before initiation of rituximab treatment. 4.Patients must be able to adhere to the study appointments and other protocol requirements. 5. Patients must be capable of giving informed consent and the consent must have been obtained prior to the study related procedures.
Exclusion criteria
Exclusion criteria: 1.Treatment with any investigational drug within the previous 3 months. 2.Pregnancy or breast-feeding. 3.Previous exposure to radioactivity (nuclear imaging) in the year preceding inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visualized tissue biodistribution patterns of RA patients by [89Zr]rituximab PET-CT at initiation of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. [89Zr]rituximab PET-CT images of RA responders and non-responders to rituximab treatment. 2. Analysed lymphoid tissue response to rituximab treatment in relation to clinical outcome and imaging data. | — |
Countries
Netherlands
Outcome results
None listed